A prospective, randomized therapeutic trial for schistosomal specific nephropathy

Area of Science:

• Nephrology
• Immunology
• Infectious Diseases

Background:

• Schistosomal nephropathy is a specific kidney disease caused by Schistosoma parasites.
• Established disease presents challenges for therapeutic intervention.
• Accurate diagnosis relies on identifying schistosomal antigens (CAA, CCA) and antibodies in renal tissue.

Purpose of the Study:

• To evaluate the efficacy of different therapeutic regimens in patients with schistosomal nephropathy.
• To compare the effects of anti-schistosomal drugs alone versus combined with immunosuppressants (prednisolone or cyclosporine).

Main Methods:

• A randomized study involving 26 patients with schistosomal nephropathy.
• Three treatment groups: Group I (anti-schistosomal drugs), Group II (drugs + prednisolone), Group III (drugs + cyclosporine).
• Patients were followed for 12 months, assessing proteinuria, kidney function, and disease remission.

Main Results:

• Complete remission of proteinuria occurred in 2 cases in Group II and 1 case in Group III; none in Group I.
• Partial remission was observed in 1 case (Group I), 3 cases (Group II), and 1 case (Group III).
• Kidney function improved in 2 cases (Group II) but deteriorated in 1 case each in Group I and Group III.

Conclusions:

• Current therapeutic regimens do not induce disease regression in patients with established schistosomal nephropathy.
• Combination therapy with prednisolone or cyclosporine showed some benefit in remission but not overall regression.
• The study highlights the limited efficacy of interventions once the disease is established.